Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01456689 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01456689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01456689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Dose Escalation, Phase 1 Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
April 25, 2012
Completion date
June 5, 2019
Enrollment
79 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma